Sakura Jaya

NGS-based RNA-sequencing (RNA-Seq) is a laboratory technique that uses next-generation sequencing (NGS) technology to study the complete set of RNA transcripts in a cell or tissue. It allows researchers to understand gene expression patterns, alternative splicing, and transcript abundance.

This technique is widely used in molecular biology, genomics, disease research, and drug development. RNA-Seq provides a comprehensive view of how genes are regulated under different conditions or in response to treatments.

Key features of NGS-based RNA-sequencing include:

• High-throughput sequencing for large-scale analysis

• Detection of known and novel transcripts

123412

123412

123412

The market is expected to grow steadily with increasing adoption in drug development and clinical trials. Innovations like virtual patients and AI-driven models will further enhance capabilities.

Emerging economies will contribute to expansion with growing healthcare investment.

Discover future outlook at the Biosimulation Market.

Investment opportunities abound in developing advanced filter integrity testing technologies and expanding into untapped regions. The rising biopharmaceutical industry and stringent regulatory requirements offer lucrative prospects.

Startups focusing on IoT-enabled testers and data analytics can capture niche segments. Additionally, partnerships with pharmaceutical manufacturers accelerate market penetration.

Explore related investment trends at the Endometrial Cancer Market.

The Drug Repurposing Market encompasses a variety of therapeutic segments that are driving its robust growth. Key areas include oncology, neurology, infectious diseases, and rare diseases, each presenting unique opportunities for repurposed drugs.

Oncology is one of the largest and most active segments, due to the high unmet needs in cancer treatment. Repurposed drugs offer new mechanisms of action and treatment combinations, addressing drug resistance and improving patient outcomes.

Neurological disorders such as Alzheimer’s, Parkinson’s, and multiple sclerosis are also significant focuses, as existing drugs are explored for neuroprotective and symptomatic relief benefits.

The infectious disease segment gained momentum during the COVID-19 pandemic, where rapid repurposing efforts sought effective antiviral and antibacterial treatments.

Rare diseases benefit from repurposing by providing faster and more affordable access to therapies, given the often limited commercial incentive for novel drug development.

Segmentation by drug type shows small molecules dominating, due to their well-established safety profiles…

Market Growth and Key Drivers

The Healthcare Contract Research Outsourcing Market is experiencing a robust growth trajectory, valued at an estimated USD 68.30 billion in 2025 and projected to reach USD 249.89 billion by 2034, with a striking CAGR of 15.50%. This significant expansion is primarily fueled by the pharmaceutical industry’s increasing need to reduce R&D costs and accelerate the drug development process. By outsourcing research to Contract Research Organizations (CROs), companies can access specialized expertise, cutting-edge technology, and a global network of clinical trial sites without the high overhead of in-house teams. The rising complexity of drug development for innovative therapies, such as biologics and precision medicine, also necessitates the specialized knowledge that CROs provide.

The market is also being driven by the expiration of patents for blockbuster drugs, which is compelling pharmaceutical companies to invest heavily in new drug pipelines to remain competitive. This shift, coupled with the pressure…